Here's What Key Metrics Tell Us About Agilent (A) Q2 Earnings

For the quarter ended April 2025, Agilent Technologies (A) reported revenue of $1.67 billion, up 6% over the same period last year. EPS came in at $1.31, compared to $1.22 in the year-ago quarter.The reported revenue compares to the Zacks Consensus Estimate of $1.63 billion, representing a surprise of +2.64%. The company delivered an EPS surprise of +3.97%, with the consensus EPS estimate being $1.26.While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.Here is how Agilent performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts: Revenue by End Markets- Pharmaceutical: $603 million versus the two-analyst average estimate of $572.63 million. The reported number represents a year-over-year change of +11.3%. Revenue by End Markets- Academia and Government: $135 million compared to the $145.13 million average estimate based on two analysts. The reported number represents a change of -2.9% year over year. Revenue by End Markets- Diagnostics and Clinical: $255 million versus the two-analyst average estimate of $247.93 million. The reported number represents a year-over-year change of +6.7%. Net Revenue- Agilent Crosslab Group: $713 million versus $697.53 million estimated by two analysts on average. Compared to the year-ago quarter, this number represents a +77.4% change. Revenue by End Markets- Food: $147 million versus $146.05 million estimated by two analysts on average. Compared to the year-ago quarter, this number represents a +5.8% change. Revenue by End Markets- Environmental and Forensics: $159 million compared to the $159.54 million average estimate based on two analysts. The reported number represents a change of +4.6% year over year. Revenue by End Markets- Chemical and advanced materials: $369 million compared to the $370.20 million average estimate based on two analysts. The reported number represents a change of +1.9% year over year. View all Key Company Metrics for Agilent here>>>Shares of Agilent have returned +3.5% over the past month versus the Zacks S&P 500 composite's +7.4% change. The stock currently has a Zacks Rank #4 (Sell), indicating that it could underperform the broader market in the near term.Only $1 to See All Zacks' Buys and SellsWe're not kidding.Several years ago, we shocked our members by offering them 30-day access to all our picks for the total sum of only $1. No obligation to spend another cent.Thousands have taken advantage of this opportunity. Thousands did not - they thought there must be a catch. Yes, we do have a reason. We want you to get acquainted with our portfolio services like Surprise Trader, Stocks Under $10, Technology Innovators,and more, that closed 256 positions with double- and triple-digit gains in 2024 alone.See Stocks Now >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Agilent Technologies, Inc. (A): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).Zacks Investment ResearchWeiter zum vollständigen Artikel bei Zacks Weiter zum vollständigen Artikel bei Zacks